01.12.2017 | Research article | Ausgabe 1/2017 Open Access

MUC1 in lung adenocarcinoma: cross-sectional genetic and serological study
- Zeitschrift:
- BMC Cancer > Ausgabe 1/2017
Electronic supplementary material
Background
Methods
Patients and clinical samples
Patients with lung adenocarcinoma
|
Healthy volunteers
|
|||
---|---|---|---|---|
All patients
|
Genomic analysis
|
Serum analysis
|
||
Subject number
|
354
|
172
|
304
|
276
|
Age
|
65.9 ± 0.6
|
63.8 ± 0.9
|
66.6 ± 0.6
|
49.9 ± 0.4
|
Gender, Male / Female
|
195 / 159
|
95 / 77
|
164 / 140
|
228 / 48
|
Smoking, Yes / No
|
211 / 143
|
103 / 69
|
179 / 125
|
158 / 118
|
PS, ≤1 / ≥2
|
319 / 35
|
149 / 23
|
274 / 30
|
|
EGFR, Mutant / Wild / ND
|
122 / 182 / 50
|
55 / 67 / 50
|
122 / 182 / 0
|
|
T factor, ≤2 / ≥3
|
237 / 117
|
105 / 67
|
207 / 97
|
|
N factor, ≤1 / ≥2
|
180 / 174
|
72 / 100
|
156 / 148
|
|
M factor, 0 / 1
|
189 / 165
|
78 / 94
|
160 / 144
|
EGFR mutation status
DNA preparation and rs4072037 genotyping
Measurement of serum KL-6 levels
Statistical analysis
Results
The rs4072037 genotype was not associated with susceptibility to lung ADC or its prognosis
AA (%)
|
AG (%)
|
GG (%)
|
HWE
|
chi-square
|
|
---|---|---|---|---|---|
Healthy volunteers
|
186 (67.4)
|
82 (29.7)
|
8 (2.9)
|
0.979
|
ref.
|
All patients
|
116 (67.5)
|
52 (30.2)
|
4 (2.3)
|
0.891
|
0.933
|
limited to ≥T3
|
46 (68.7)
|
21 (31.3)
|
0 (0)
|
0.376
|
0.367
|
limited to ≥N2
|
65 (65.0)
|
33 (33.0)
|
2 (2.0)
|
0.772
|
0.761
|
limited to ≥M1a
|
62 (66.0)
|
28 (29.8)
|
4 (4.2)
|
0.968
|
0.811
|
Dominant model
|
Recessive model
|
|||
---|---|---|---|---|
OR (95% CI)
|
P value
|
OR (95% CI)
|
P value
|
|
All patients
|
0.998 (0.665–1.498)
|
0.991
|
0.798 (0.237–2.690)
|
0.484
|
limited to ≥T3
|
0.943 (0.531–1.675)
|
0.843
|
0.971 (0.951–0.991)
|
0.172
|
limited to ≥N2
|
1.113 (0.687–1.802)
|
0.664
|
0.684 (0.143–3.275)
|
0.477
|
limited to ≥M1a
|
1.067 (0.650–1.750)
|
0.798
|
1.489 (0.438–5.062)
|
0.363
|
Serum KL-6 levels varied according to the rs4072037 genotype in HVs and patients with early stage ADC, but not in those with advanced disease
Serum KL-6 levels were significantly elevated in patients with lung ADC
Serum KL-6 levels significantly correlated with survival in patients with lung ADC
Variable
|
HR
|
95% CI.
|
P value
|
---|---|---|---|
A. Multivariate Cox proportional hazards regression model
|
|||
PS, ordinal
|
1.72
|
1.35–2.20
|
<0.001
|
EGFR, wild type / mutant
|
2.43
|
1.62–3.64
|
<0.001
|
N factor, ordinal
|
1.23
|
1.04–1.45
|
0.018
|
M factor, yes / no
|
3.33
|
2.02–5.48
|
<0.001
|
Serum KL-6, ≥600 / <600 U/mL
|
2.19
|
1.43–3.37
|
<0.001
|
B. Comparison of C statistics for each prediction model
|
|||
Prediction model
|
C index
|
95% CI.
|
P value
|
Covariates only
|
0.776
|
0.722–0.830
|
Ref.
|
Covariates + serum KL-6
|
0.790
|
0.736–0.843
|
0.036
|